Pharmaceuticals and Healthcare · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 3.81% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 0.02% | < 30% | Pass |
| Interest-bearing investments / market cap | 0.73% | < 30% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free3.81% of any dividend from ALKEM should be given to charity. Calculate your amount →
Short‑ and medium‑term returns are mildly negative, the 50‑day is below the 200‑day and the stock sits somewhat below its 52‑week high, describing a gentle downtrend or drift lower. Low volatility suggests a relatively orderly, gradual decline rather than sharp moves.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.